Norway Mrna Therapeutics Market Size & Outlook, 2024-2030
- Biotechnology
- RNA analysis
- MRNA Therapeutics Market Outlook
- RNA analysis
Global Market
Related Markets
Ask Prism AI about the mrna therapeutics market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
Norway mrna therapeutics market highlights
- The Norway mrna therapeutics market generated a revenue of USD 40.4 million in 2023 and is expected to reach USD 99.2 million by 2030.
- The Norway market is expected to grow at a CAGR of 13.7% from 2024 to 2030.
- In terms of segment, infectious diseases was the largest revenue generating application in 2023.
- Infectious Diseases is the most lucrative application segment registering the fastest growth during the forecast period.
Mrna therapeutics market data book summary
| Market revenue in 2023 | USD 40.4 million |
| Market revenue in 2030 | USD 99.2 million |
| Growth rate | 13.7% (CAGR from 2023 to 2030) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Infectious Diseases |
| Historical data | 2021 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Infectious Diseases |
| Key market players worldwide | Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global mrna therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany mrna therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,883.7 million by 2030.
Growing research on mRNA vaccines is anticipated to boost mRNA therapeutics to a certain extent. On the other hand, increased research activities led to the analysis of various adverse effects associated with mRNA-based COVID-19 vaccines, such as myocarditis.
For instance, in October 2021, Norway suspended the use of Moderna’s COVID-19 vaccine for men younger than 30 years and all people under 18 years due to its rare association with endocarditis & myocarditis. Such instances might impede the mRNA therapeutics market growth in Norway.
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
MRNA Therapeutics Market Scope
MRNA Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| BioNTech SE ADR | View profile | 6,133 | An der Goldgrube 12, Mainz, RP, Germany, D-55131 | www.biontech.de |
| Moderna Inc | View profile | 5,600 | 200 Technology Square, Cambridge, MA, United States, 02139 | www.modernatx.com |
| CureVac NV Ordinary Shares | View profile | 1,100 | Friedrich-Miescher-Strasse 15, Tubingen, BW, Germany, 72076 | www.curevac.com |
| Arcturus Therapeutics Holdings Inc | View profile | 180 | 10628 Science Center Drive, Suite 250, San Diego, CA, United States, 92121 | www.arcturusrx.com |
| Argos Therapeutics | View profile | 101-250 | Durham, North Carolina, United States, North America | www.argostherapeutics.com |
| ETHRIS | View profile | 101-250 | Planegg, Bayern, Germany, Europe | ethris.com/ |
Norway MRNA Therapeutics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to MRNA Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Infectious Diseases was the largest segment with a revenue share of 100.0% in 2023.
Horizon Databook has segmented the Norway mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
Growing research on mRNA vaccines is anticipated to boost mRNA therapeutics to a certain extent. On the other hand, increased research activities led to the analysis of various adverse effects associated with mRNA-based COVID-19 vaccines, such as myocarditis.
For instance, in October 2021, Norway suspended the use of Moderna’s COVID-19 vaccine for men younger than 30 years and all people under 18 years due to its rare association with endocarditis & myocarditis. Such instances might impede the mRNA therapeutics market growth in Norway.
- Norway Mrna Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2030)
- Infectious Diseases
- Oncology
- Rare Genetic Diseases
- Respiratory Diseases
- Others
- Norway Mrna Therapeutics Market Type Outlook (Revenue, USD Million , 2021-2030)
- Prophylactic
- Therapeutic
- Norway Mrna Therapeutics Market End Use Outlook (Revenue, USD Million , 2021-2030)
- Hospitals & Clinics
- Research Organizations
- Others
Reasons to subscribe to MRNA Therapeutics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of MRNA Therapeutics Market Outlook databook
- Our clientele includes a mix of MRNA Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway MRNA Therapeutics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Norway MRNA Therapeutics Market Outlook from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Norway Mrna Therapeutics Market, 2021-2030 (US$M)
Norway mrna therapeutics market statistics, by application, 2021-2030 (US$M)
